| 1 Clinically important response (defined by study) |
1 |
|
Risk Ratio (M‐H, Random, 95% CI) |
Subtotals only |
| 1.1 short term (up to 12 weeks) |
1 |
26 |
Risk Ratio (M‐H, Random, 95% CI) |
0.67 [0.13, 3.35] |
| 2 Global state: 1. Average endpoint score of CGI scales (high = poor) |
1 |
|
Mean Difference (IV, Random, 95% CI) |
Subtotals only |
| 2.1 short term (up to 12 weeks) |
1 |
26 |
Mean Difference (IV, Random, 95% CI) |
0.07 [‐0.77, 0.91] |
| 3 Mental state: 2a. Average endpoint scores (BPRS, high = poor) |
1 |
|
Mean Difference (IV, Random, 95% CI) |
Subtotals only |
| 3.1 BPRS endpoint total scale score ‐ short term (up to 12 weeks) |
1 |
25 |
Mean Difference (IV, Random, 95% CI) |
‐1.98 [‐12.96, 9.00] |
| 3.2 BPRS positive subscale score ‐ short term (up to 12 weeks) |
1 |
25 |
Mean Difference (IV, Random, 95% CI) |
‐0.15 [‐4.22, 3.92] |
| 3.3 BPRS negative subscale score ‐ short term (up to 12 weeks) |
1 |
25 |
Mean Difference (IV, Random, 95% CI) |
‐1.54 [‐3.94, 0.86] |
| 3.4 BPRS hostile subscale score ‐ short term (up to 12 weeks) |
1 |
25 |
Mean Difference (IV, Random, 95% CI) |
0.92 [‐2.21, 4.05] |
| 4 Mental state: 2b. Average endpoint score of various scales (high = poor) ‐ short term (up to 12 weeks) (skewed data) |
|
|
Other data |
No numeric data |
| 4.1 BPRS anxiety/depression subscale score |
|
|
Other data |
No numeric data |
| 4.2 BPRS activation subscale score |
|
|
Other data |
No numeric data |
| 5 Adverse effects: 1. Anticholinergic effect |
1 |
|
Risk Ratio (M‐H, Random, 95% CI) |
Subtotals only |
| 5.1 blurred vision ‐ short term (up to 12 weeks) |
1 |
25 |
Risk Ratio (M‐H, Random, 95% CI) |
1.08 [0.18, 6.53] |
| 5.2 dry mouth ‐ short term (up to 12 weeks) |
1 |
25 |
Risk Ratio (M‐H, Random, 95% CI) |
1.08 [0.18, 6.53] |
| 5.3 urinary hesitancy ‐ short term (up to 12 weeks) |
1 |
25 |
Risk Ratio (M‐H, Random, 95% CI) |
5.38 [0.28, 101.96] |
| 6 Adverse effects: 2. Central nervous system |
1 |
|
Risk Ratio (M‐H, Random, 95% CI) |
Subtotals only |
| 6.1 anxiety ‐ short term (up to 12 weeks) |
1 |
25 |
Risk Ratio (M‐H, Random, 95% CI) |
0.54 [0.06, 5.24] |
| 6.2 headache ‐ short term (up to 12 weeks) |
1 |
25 |
Risk Ratio (M‐H, Random, 95% CI) |
0.77 [0.33, 1.79] |
| 6.3 lethargy ‐ short term (up to 12 weeks) |
1 |
25 |
Risk Ratio (M‐H, Random, 95% CI) |
0.81 [0.23, 2.91] |
| 6.4 insomnia ‐ short term (up to 12 weeks) |
1 |
25 |
Risk Ratio (M‐H, Random, 95% CI) |
1.81 [0.55, 5.98] |
| 6.5 somnolence ‐ short term (up to 12 weeks) |
1 |
25 |
Risk Ratio (M‐H, Random, 95% CI) |
0.87 [0.30, 2.49] |
| 7 Adverse effects: 3. Gastrointestinal |
1 |
|
Risk Ratio (M‐H, Random, 95% CI) |
Subtotals only |
| 7.1 constipation ‐ short term (up to 12 weeks) |
1 |
25 |
Risk Ratio (M‐H, Random, 95% CI) |
9.69 [0.58, 163.02] |
| 7.2 diarrhoea ‐ short term (up to 12 weeks) |
1 |
25 |
Risk Ratio (M‐H, Random, 95% CI) |
0.22 [0.01, 4.08] |
| 7.3 dyspepsia ‐ short term (up to 12 weeks) |
1 |
25 |
Risk Ratio (M‐H, Random, 95% CI) |
3.25 [0.39, 27.15] |
| 7.4 nausea/vomiting ‐ short term (up to 12 weeks) |
1 |
25 |
Risk Ratio (M‐H, Random, 95% CI) |
0.72 [0.14, 3.61] |
| 8 Adverse effects: 4. Other adverse events |
1 |
|
Risk Ratio (M‐H, Random, 95% CI) |
Subtotals only |
| 8.1 urinary frequency ‐ short term (up to 12 weeks) |
1 |
25 |
Risk Ratio (M‐H, Random, 95% CI) |
0.36 [0.02, 8.05] |
| 8.2 orthostasis ‐ short term (up to 12 weeks) |
1 |
25 |
Risk Ratio (M‐H, Random, 95% CI) |
0.43 [0.10, 1.83] |
| 8.3 increased appetite ‐ short term (up to 12 weeks) |
1 |
25 |
Risk Ratio (M‐H, Random, 95% CI) |
0.72 [0.14, 3.61] |
| 8.4 dizziness ‐ short term (up to 12 weeks) |
1 |
25 |
Risk Ratio (M‐H, Random, 95% CI) |
0.36 [0.04, 3.02] |
| 9 Adverse effects: 5. Average endpoint weight loss (kg) (skewed data) |
|
|
Other data |
No numeric data |
| 9.1 short term (up to 12 weeks) |
|
|
Other data |
No numeric data |
| 10 Leaving the study early |
1 |
|
Risk Ratio (IV, Random, 95% CI) |
Subtotals only |
| 10.1 inefficacy ‐ short term (up to 12 weeks) |
1 |
25 |
Risk Ratio (IV, Random, 95% CI) |
1.08 [0.08, 15.46] |
